Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells.

Literature DB >> 8040893

N-(4-hydroxyphenyl)retinamide: a potent inducer of apoptosis in human neuroblastoma cells.

A Mariotti¹, E Marcora, G Bunone, A Costa, U Veronesi, M A Pierotti, G Della Valle.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：
DNA, Neoplasm
Fenretinide

Year: 1994 PMID： 8040893 DOI： 10.1093/jnci/86.16.1245

Source DB: PubMed Journal: J Natl Cancer Inst ISSN： 0027-8874 Impact factor: 13.506

Keyword Cloud
Cited

× No keyword cloud information.

16 in total

1. Novel retinoic acid derivative induces differentiation and growth arrest in neuroblastoma.

Authors: Raoud Marayati; Adele P Williams; Laura V Bownes; Colin H Quinn; Jerry E Stewart; Elizabeth Mroczek-Musulman; Venkatram R Atigadda; Elizabeth A Beierle
Journal: J Pediatr Surg Date: 2020-02-28 Impact factor: 2.545

Review 2. Clinical development of fenretinide as an antineoplastic drug: Pharmacology perspectives.

Authors: Jason P Cooper; C Patrick Reynolds; Hwangeui Cho; Min H Kang
Journal: Exp Biol Med (Maywood) Date: 2017-04-21

3. Preclinical evaluation of lestaurtinib (CEP-701) in combination with retinoids for neuroblastoma.

Authors: Robin E Norris; Jane E Minturn; Garrett M Brodeur; John M Maris; Peter C Adamson
Journal: Cancer Chemother Pharmacol Date: 2011-04-12 Impact factor: 3.333

4. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group.

Authors: Judith G Villablanca; Wendy B London; Arlene Naranjo; Patrick McGrady; Matthew M Ames; Joel M Reid; Renee M McGovern; Sarah A Buhrow; Hollie Jackson; Enno Stranzinger; Brenda J Kitchen; Paul M Sondel; Marguerite T Parisi; Barry Shulkin; Gregory A Yanik; Susan L Cohn; C Patrick Reynolds
Journal: Clin Cancer Res Date: 2011-09-09 Impact factor: 12.531

5. Phase II trial of fenretinide in advanced renal carcinoma.

Authors: Ulka Vaishampayan; Lance K Heilbrun; Ralph E Parchment; Vikash Jain; James Zwiebel; Ramesh R Boinpally; Patricia LoRusso; Maha Hussain
Journal: Invest New Drugs Date: 2005-03 Impact factor: 3.850

6. p75NTR: an enhancer of fenretinide toxicity in neuroblastoma.

Authors: Veena Ganeshan; John Ashton; Nina F Schor
Journal: Cancer Chemother Pharmacol Date: 2013-01-13 Impact factor: 3.333

7. Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Authors: Bryan J Schneider; Francis P Worden; Shirish M Gadgeel; Ralph E Parchment; Collette M Hodges; James Zwiebel; Rodney L Dunn; Antoinette J Wozniak; Michael J Kraut; Gregory P Kalemkerian
Journal: Invest New Drugs Date: 2009-02-19 Impact factor: 3.850